AVXL
Anavex Life Sciences Corp.NASDAQHealthcare$2.99-3.55%ClosedMarket Cap: $277.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.10
P/S
0.00
EV/EBITDA
-3.63
DCF Value
$1.17
FCF Yield
-12.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.8%
ROA
-30.0%
ROIC
-35.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $0.00 | NaN% | $-6.8M | $-5.7M | $-0.06 | — |
| Q4 2025 | $0.00 | NaN% | $-10.8M | $-9.8M | $-0.11 | — |
| FY 2025 | $0.00 | NaN% | $-51.4M | $-46.4M | $-0.54 | — |
| Q3 2025 | $0.00 | NaN% | $-14.5M | $-13.2M | $-0.16 | — |
| Q2 2025 | $0.00 | NaN% | $-12.5M | $-11.2M | $-0.13 | — |
| Q1 2025 | $0.00 | NaN% | $-13.6M | $-12.1M | $-0.14 | — |
| Q4 2024 | $0.00 | NaN% | $-14.3M | $-11.6M | $-0.14 | — |
| FY 2024 | $0.00 | NaN% | $-52.9M | $-43.0M | $-0.52 | — |
| Q3 2024 | $0.00 | NaN% | $-14.6M | $-12.2M | $-0.14 | — |
| Q2 2024 | $0.00 | NaN% | $-12.6M | $-10.5M | $-0.13 | — |
| Q1 2024 | $0.00 | NaN% | $-11.4M | $-8.6M | $-0.10 | — |
| Q4 2023 | $0.00 | NaN% | $-12.7M | $-10.1M | $-0.13 | — |